Therefore, we aim to investigate new treatments derived from fungal metabolites using molecular docking and ADMET methods, as well as to examine their therapeutic multitarget potential against three important AD target proteins (GSK-3β, NMDA receptor, and BACE-1). Here, BACE1 is linked to Alzheimer disease.